News

People with multiple sclerosis (MS) are among the high-risk groups advised to avoid dental amalgams — silver-colored fillings that are 50% mercury — under new recommendations issued by the U.S. Food and Drug Administration (FDA). Amalgams can be used by dentists to restore the structure and surfaces of teeth damaged by decay.

The National Multiple Sclerosis Society has awarded a two-year, $373,000 Fast Forward grant to researchers at the University of California Riverside School of Medicine to identify compounds best able to replace myelin lost over the course of multiple sclerosis (MS), according to a press release.

When safety measures like isolation are in place, neither disease-modifying therapy (DMT) use nor greater physical disability appear to heighten the risk of people with multiple sclerosis (MS) contracting COVID-19, a large U.K. registry-based study found. Preliminary study data also suggested that these factors do not affect…

Low blood levels of ferritin — the main form of iron stored in cells — are significantly associated with more severe depressive symptoms and poorer quality of life in multiple sclerosis (MS) patients, a small study from Poland reports. Data showed no link between the levels of other measures of…

The use of certain disease-modifying therapies (DMTs) such as rituximab and Ocrevus (ocrelizumab), which lower the number of a patient’s immune B-cells, may increase the odds of developing a more severe COVID-19 disease course for people with multiple sclerosis (MS), a study suggests. The study, which includes data from the…

The U.S. Food and Drug Administration (FDA) has approved Cipla’s dimethyl fumarate capsules, a generic version of Biogen’s Tecfidera, to treat adults with relapsing forms of multiple sclerosis (MS), the company announced in a press release. This generic is packaged as 120 mg or 240 mg…

Dutch Amarna Therapeutics announced a research collaboration with Spanish Progreso y Salud Foundation (FPS) to investigate the efficacy of its gene therapy delivery technology in multiple sclerosis (MS) and diabetes. MS is thought to be caused by immune-mediated inflammation that damages myelin — an insulating sheath around nerve…

Patients with multiple sclerosis (MS) report moderate scores in mental and physical health, as measured by three, well-established quality-of-life scales, according to an analysis of published literature. The study, “Global, regional and national quality of life in patients with multiple sclerosis: a global systematic review and…

People with multiple sclerosis (MS) show a high occurrence of comorbidities — two diseases occurring in one person at the same time — with psychiatric and cardiovascular diseases being the most common, a new study reports. Having another co-existing disorder was found to have an impact on MS…

People with multiple sclerosis (MS) have a higher burden of mental disorders than healthy people or people with rheumatoid arthritis, a French population-based study suggests. The study, “Prevalence of mental disorders is higher in patients with multiple sclerosis than in the general population or in patients with…

The U.S. Food and Drug Administration (FDA) has accepted an investigational new drug application (IND) for ANK-700, a treatment candidate for multiple sclerosis (MS) that is being developed by the Swiss company Anokion. With this approval, Anokion can enter clinical testing and is planning to…

Older age at disease-modifying therapy (DMT) discontinuation is the main predictive factor of sustained “no evidence of disease activity” (NEDA) in people starting DMT immediately after being diagnosed with clinically isolated syndrome (CIS), according to a study in Austria. In particular, patients discontinuing DMT at age 45 or…

Regulatory T-cells (Tregs) — immune cells that normally dampen immune and inflammatory responses by inhibiting the activity of pro-inflammatory immune cells — enabled mice in a model of multiple sclerosis to partly recover from limb and tail paralysis, scientists reported. Tregs can do this by preventing a subtype of…

People in Texas with multiple sclerosis (MS) and other medical conditions now have access to cannabis-infused lozenges, Surterra Texas announced. Under a Texas Compassionate Use Program, cannabis-containing therapies may be prescribed to help treat various neurological and other disorders, including terminal cancer, spasticity,…

The development of a diagnostic test using neurofilament light chain (NfL) — a biomarker for nerve cell damage — for people with multiple sclerosis (MS) will be part of a collaboration program between Siemens Healthineers and Novartis. The goal of this new collaboration is to design, develop,…

The National Institutes of Health (NIH) awarded a $2.3 million grant to a bioengineer at Indiana University’s Luddy School of Informatics, Computing and Engineering to improve diagnosis and treatment of autoimmune diseases, such as multiple sclerosis (MS). The project aims to find ways to detect disease-associated cells based on their ability…

Among oral sphingosine-1-phosphate (S1P) receptor modulators for multiple sclerosis (MS), Novartis’s Gilenya (fingolimod) remains physicians’ favorite in the U.S., but prescriptions of recently-launched Bristol Myers Squibb’s Zeposia (ozanimod) are beginning to rise, according to a survey conducted by Spherix Global Insights. Also, COVID-19 not…

More than 2.8 million people worldwide are now estimated to be living with multiple sclerosis (MS), including about 1 million in the United States, an update to the Atlas of MS reports. An increase since its previous update, this number translates to someone, somewhere in the world, being newly diagnosed with…

After a pregnancy or childbirth, most women who went on to develop clinically isolated syndrome (CIS) did so about three years later than those who were never pregnant, a large and multicenter study reported. Multiple pregnancies or births, however, were not seen to further affect CIS onset. More research is…

The National Multiple Sclerosis Society, together with the Lewin Group, has launched a survey to assess the economic impact multiple sclerosis (MS) has on patients and their families. In the survey, which can be found here, MS patients and/or their family members are asked to answer…

Fatigue is the most impactful symptom on daily functioning in people with relapsing forms of multiple sclerosis (MS) and is more severe in patients with relapse, pain, depression, and sleep disorders, according to a U.S.-based survey. The results were based mostly on a new MS-specific tool called the Fatigue Symptoms…

Tysabri (natalizumab) is superior to other disease-modifying therapies (DMTs) at improving balance and vision, easing bladder problems and sexual dysfunction, and alleviating anxiety in people with multiple sclerosis (MS), according to data from an Australian study. The study’s findings were presented at…

AB Science’s lead candidate masitinib safely and effectively delays disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS), according to top-line data from a clinical trial. The therapy was found to significantly lower the risk of first and confirmed (three-month) disability progression, and to reduce…

Early use of Ocrevus (ocrelizumab) significantly slows shrinkage of the thalamus — a brain region involved in sensory and motor functions — in people with relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS), according to new analyses from three Phase 3 trials that compared immediate use with a two-year…

Long-term treatment with Tecfidera (dimethyl fumarate) continues to be safe and effective at reducing the frequency of relapses and disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), according to 13-year data from a Phase 3 extension study. The study findings were presented at MSVirtual2020 by Ralf…

Continuous treatment with Aubagio (teriflunomide) can safely lower the risk of relapses and disability progression in children with relapsing forms of multiple sclerosis (MS), according to interim data from the open-label extension of a Phase 3 trial. These findings were detailed at MSVirtual2020 by Tanuja Chitnis, MD,…

Cognitive problems can persist into adulthood in people whose multiple sclerosis (MS) began in childhood or adolescence, and are linked to neurological issues and delays in treatment initiation, a study reports. Early use of disease-modifying therapies (DMTs) and of approaches designed to preserve cognition should be encouraged for pediatric…

Most children and adolescents with pediatric-onset multiple sclerosis (POMS), especially those treated intravenously with a disease-modifying therapy (DMT), achieve no evidence of disease activity within two years of diagnosis, according to a real-life study from the U.S. Patients whose DMTs are infused into a vein (intravenous treatment) are more likely…

Compared to low-efficacy disease-modifying therapies (DMTs), high-efficacy medications are more effective at slowing the loss of nerve cells making up different layers of the retina — the region at the back of the eye that enables one to see — in patients with relapsing-remitting…

Remyelination — or the restoration of lost myelin, the protective sheath surrounding nerve cell fibers — in multiple sclerosis (MS) depends mainly on pre-existing oligodendrocytes (myelin-producing cells), rather than on newly-generated oligodendrocytes, according to a recent study. The data also showed that perineuronal, or satellite,…